Document is current
Any future updates will be listed below
-
Authors
Widjaja, Anissa A. https://orcid.org/0000-0001-9404-7608
Viswanathan, Sivakumar https://orcid.org/0000-0002-9263-1656
Shekeran, Shamini G.
Adami, Eleonora
Lim, Wei-Wen https://orcid.org/0000-0003-0311-943X
Chothani, Sonia
Tan, Jessie
Goh, Joyce Wei Ting https://orcid.org/0000-0001-9313-4195
Chen, Hui Mei https://orcid.org/0000-0001-7788-1334
Lim, Sze Yun
Boustany-Kari, Carine M.
Hawkins, Julie
Petretto, Enrico https://orcid.org/0000-0003-2163-5921
Hübner, Norbert https://orcid.org/0000-0002-1218-6223
Schafer, Sebastian https://orcid.org/0000-0002-6909-8275
Coffman, Thomas M.
Cook, Stuart A. https://orcid.org/0000-0001-6628-194X
-
Funding
Funding for this research was provided by:
MOH | National Medical Research Council (NMRC/OFYIRG/0053/2017, OFIRG21nov-0038, NMRC/STaR/0029/2017, MOH‐CIRG18nov‐0002)
- License Information
-
More Information
Article History
Received: 2 November 2021
Accepted: 27 November 2022
First Online: 5 December 2022
Competing interests
: A.A.W., S.S., and S.A.C. are co-inventors of the US Patent 11339216 (Treatment of kidney injury). S.S. and S.A.C are co-inventors of the published patents: WO/2017/103108 (TREATMENT OF FIBROSIS), WO/2018/109174 (IL11 ANTIBODIES), WO/2018/109170 (IL11RA ANTIBODIES). S.S. and S.A.C. are co-founders and shareholders of Enleofen Bio PTE LTD, a company that made anti-IL11 therapeutics, which were acquired for further development by Boehringer Ingelheim in 2019. The remaining authors declare no competing interests.
